Dirk Thomas

First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa

Dirk Thomas, Friederike Kanefendt, Stephan Schwers et al. · Journal of Thrombosis and Haemostasis · 2021 · 81 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics

Dirk Thomas, Kirstin Thelen, Stefanie Kraff et al. · Research and Practice in Thrombosis and Haemostasis · 2019 · 76 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects

Michael Böettcher, Dirk Thomas, Wolfgang Mueck et al. · European Journal of Clinical Pharmacology · 2020 · 72 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

Metabolism and Pharmacokinetic Drug–Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies

Michael Böettcher, Michael Gerisch, Maximilian T. Lobmeyer et al. · Clinical Pharmacokinetics · 2020 · 57 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

The pharmacokinetics of nedocromil sodium, a new drug for the treatment of reversible obstructive airways disease, in human volunteers and patients with reversible obstructive airways disease.

M G Neale, Kristen Brown, R. Foulds et al. · British Journal of Clinical Pharmacology · 1987 · 37 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16